MVZ Medical Center Duesseldorf GmbH

The department focuses on testing innovative neoadjuvant regimens that aim to shrink tumors before surgery, comparing novel agents with standard chemotherapy.

• Evaluation of antibody‑drug conjugates in early HER2‑positive disease
• Assessment of response rates using dynamic molecular markers
• Safety monitoring for high‑grade adverse events

These studies seek to improve surgical outcomes and long‑term disease‑free survival for patients at MVZ Medical Center Duesseldorf GmbH.

Research examines the addition of CDK4/6 inhibitors to endocrine therapy after primary treatment, targeting hormone‑receptor‑positive, HER2‑negative early breast cancer.

• Comparison of ribociclib plus endocrine therapy versus chemotherapy
• Investigation of extended treatment duration on invasive disease‑free survival
• Evaluation of intermediate‑risk patient subgroups

The goal is to reduce recurrence risk while maintaining quality of life for women receiving care at the center.

The unit conducts trials of next‑generation antibody‑drug conjugates for HER2‑positive breast cancer, aiming to enhance tumor targeting while limiting systemic toxicity.

• Direct comparison of novel ADCs with standard trastuzumab‑based regimens
• Measurement of pathological complete response rates
• Long‑term monitoring of distant disease‑free survival

Findings may establish more effective adjuvant options for high‑risk patients at the Düsseldorf site.

Studies evaluate the synergy of oral selective estrogen receptor degraders (SERDs) with PARP inhibitors in patients whose tumors carry BRCA1/2 mutations.

• Assessment of progression‑free survival in advanced HR+/HER2‑ disease
• Safety profiling of combined oral agents
• Exploration of biomarker‑guided patient selection

The aim is to offer a targeted, less invasive option for individuals with genetically defined breast cancer.

The center investigates checkpoint inhibitor strategies combined with chemotherapy for low‑risk, triple‑negative tumors, seeking to boost immune‑mediated tumor clearance.

• Evaluation of pembrolizumab added to standard neoadjuvant chemotherapy
• Tracking of pathological complete response and survival endpoints
• Safety assessment of immune‑related adverse events

Successful outcomes could expand immunotherapy use beyond metastatic settings at MVZ Medical Center Duesseldorf.

Research focuses on reducing treatment intensity for intermediate‑risk patients while preserving efficacy, using genomic and clinical markers to guide decisions.

• Non‑inferiority trials comparing ribociclib‑based regimens with prior chemotherapy
• Patient‑reported outcome measures on quality of life
• Time‑to‑next‑treatment analyses as a surrogate for benefit

These efforts aim to personalize care pathways and improve survivorship experiences at the Düsseldorf facility.